A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Novartis Investigative Site, Torino

Novartis Investigative Site, Genova

Novartis Investigative Site, San Donato Milanese

Novartis Investigative Site, Milan

Novartis Investigative Site, Milan

Novartis Investigative Site, Milan

Novartis Investigative Site, Bergamo

Novartis Investigative Site, Brescia

Novartis Investigative Site, Pavia

Novartis Investigative Site, Udine

Novartis Investigative Site, Trieste

Novartis Investigative Site, Padua

Novartis Investigative Site, Verona

Novartis Investigative Site, Bologna

Novartis Investigative Site, Modena

Novartis Investigative Site, Reggio Emilia

Novartis Investigative Site, Parma

Novartis Investigative Site, Mantova

Novartis Investigative Site, Florence

Novartis Investigative Site, Siena

Novartis Investigative Site, Lucca

Novartis Investigative Site, Pisa

Novartis Investigative Site, Grosseto

Novartis Investigative Site, Ancona

Novartis Investigative Site, Macerata

Novartis Investigative Site, Chieti

Novartis Investigative Site, L’Aquila

Novartis Investigative Site, Bari

Novartis Investigative Site, Brindisi

Novartis Investigative Site, Lecce

Novartis Investigative Site, Napoli

Novartis Investigative Site, Benevento

Novartis Investigative Site, Catanzaro

Novartis Investigative Site, Erice

Novartis Investigative Site, Catania

Novartis Investigative Site, Messina

Novartis Investigative Site, Cagliari

Novartis Investigative Site, Terracina

Novartis Investigative Site, Perugia

Novartis Investigative Site, Roma

Novartis Investigative Site, Roma

Novartis Investigative Site, Roma

Novartis Investigative Site, Roma

Novartis Investigative Site, Roma

Novartis Investigative Site, Terni